WuXi AppTec's Recognition in Extel's 2025 Asia Leadership Rankings

On June 17, 2025, WuXi AppTec, a global leader in the provision of comprehensive research, development, and manufacturing services for the pharmaceutical and life sciences sectors, was honored among the top 10 "Most Honored Companies" in the prestigious Extel rankings, formerly known as Institutional Investor. This recognition highlights the company’s commitment to delivering superior healthcare solutions and innovative therapies globally.

WuXi AppTec was selected from an extensive pool of over 1,600 companies spanning 18 different sectors in Asia excluding Japan and ANZ. The Extel rankings are grounded in a survey of investment professionals, making this acknowledgment a testament to WuXi's success in facilitating high-quality patient care. The firm empowers its clients to provide innovative therapeutic solutions worldwide.

Particularly noteworthy, WuXi AppTec excelled in the following categories within the healthcare, pharmaceutical, and biotechnology sectors:

- Best CEO
- Best CFO
- Best Corporate Board
- Best IR Program
- Best ESG Program

This commendation illustrates how WuXi AppTec's unique CRDMO (Contract Research, Development, and Manufacturing Organization) model continues to drive sustainable business growth while supporting the industry, patients, and clients, ultimately creating long-term value for shareholders.

The Extel annual survey is a renowned indicator of the global capital market landscape. This year, over 6,300 portfolio managers and analysts from 1,324 institutions, comprising 1,167 buy-side firms and 157 sell-side firms, participated in the evaluation of 1,668 companies and 2,367 executives from 18 sectors in Asia.

With WuXi AppTec, clients are empowered to provide cutting-edge patient care by prioritizing customer needs and fostering scientific innovations. The company adeptly utilizes novel molecular possibilities through its state-of-the-art CRDMO model, offering seamless support throughout the entire drug development process while reducing research and delivery costs, all while maintaining the highest quality standards.

About WuXi AppTec

WuXi AppTec operates globally with a presence in Asia, Europe, and North America, delivering an extensive suite of research and manufacturing services that enable the global pharmaceutical and biotech industry to advance discoveries and provide groundbreaking treatments to patients. Through its distinctive business models, WuXi AppTec offers an integrated end-to-end service portfolio that encompasses chemical drug CRDMO, biological research, preclinical testing, and clinical research services. This enables clients to boost productivity for advanced healthcare products with cost-effective and efficient solutions.

For four consecutive years, WuXi AppTec has received an AA ESG rating from MSCI, affirming its commitment to sustainability. The company’s open-access platform allows approximately 6,000 clients from over 30 countries to improve the health of underserved populations, driving forward the vision that "every medicine can be made and every disease can be treated."

This accolade serves not only as a validation of WuXi AppTec’s initiatives within the healthcare space but also emphasizes the significant impact that their CRDMO model is having in the industry and on patient care globally.